Skip to content

Study on Early Diagnosis and Prognostic Prediction of Post-Stroke Cognitive Impairment Based on an Integrated Model of Multidimensional Biomarker

Study on Early Diagnosis and Prognostic Prediction of Post-Stroke Cognitive Impairment Based on an Integrated Model of Multidimensional Biomarker

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121648
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-stroke cognitive impairment

Interventions

Observation group:None
Control group:None

Sponsors

Wannan Rehabilitation Hospital of Anhui Province(The Fifth People’s Hospital of Wuhu)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Diagnosis consistent with the diagnostic criteria of Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China (2014 Edition) and confirmed by MRI/CT; 2. Standardized rehabilitation initiated within 1–3 months after onset and continued for >= 3 months, in accordance with Guidelines for Stroke Rehabilitation; 3. Age >= 18 years, conscious and able to cooperate with scale assessments and rehabilitation therapy; 4. Written informed consent voluntarily signed by the subject or his/her legal representative; 5. Expected follow-up duration >= 12 months.

Exclusion criteria

Exclusion criteria: 1. Previously diagnosed with dementia, mild cognitive impairment (MCI), or other neurodegenerative diseases; 2. Severe hepatic and renal insufficiency, malignant tumors, or infectious diseases (e.g., HIV, hepatitis B); 3.Coagulation dysfunction or autoimmune diseases (e.g., multiple sclerosis); 4. History of drug or alcohol abuse within the past 3 months; 5. Poor rehabilitation compliance (expected weekly rehabilitation frequency < 3 times), inability to complete follow-up, or refusal to provide serum samples.

Design outcomes

Primary

MeasureTime frame
Glial Fibrillary Acidic Protein;Neurofilament Light Chain;Lymphocyte subsets;Interleukin-6;Tumor Necrosis Factor-a;

Secondary

MeasureTime frame
C-Reactive Protein;Phosphorylated Tau at Threonine 217;Brain-Derived Tau;Amyloid ß-Protein;Homocysteine;Glycated Hemoglobin A1c;

Countries

China

Contacts

Public ContactTao Wei

Wannan Rehabilitation Hospital of Anhui Province(The Fifth People’s Hospital of Wuhu)

taowei1983@126.com+86 180 0963 7261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026